TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 13 Most Profitable Growth Stocks to Buy Right Now. Alec Stranahan of Bank of America reaffirmed a Sell rating on TG Therapeutics, Inc. with a price target of $15, based on the report released on February 27. The firm’s price target is the lowest among Wall Street analysts, based on 8 analysts covering the stock, and it reflects a 49% downside from the current levels.
The rating came after TG Therapeutics, Inc. reported its fourth-quarter financial results on February 26. Net income for the quarter reached $23 million, bringing full-year net income to $447.2 million. The company generated total global revenue of $616 million for 2025, including $594 million from U.S. BRIUMVI net product sales and $12.8 million from Neuraxpharm.
Operating expenses for the year reached about $328 million. For 2026, operating expenses are projected at $350 million, plus an additional $100 million for subcutaneous manufacturing and start-up activities.
TG Therapeutics, Inc. Chief Commercial Officer, Adam Waldman, commented on the outlook:
Turning to the first quarter … We expect U.S. revenue to grow sequentially over Q4 levels to approximately $185 million to $190 million.
Copyright: nimon / 123RF Stock Photo
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The company focuses on the development, commercialization, and acquisition of novel treatments for B-cell-mediated diseases across the United States and globally. It is based in Morrisville, North Carolina.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and Goldman Sachs Value Stocks: 10 Stocks to Buy.
